Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 41kWORD 10k
11 May 2020
Priority question for written answer
to the Commission
Rule 138
Simona Baldassarre (ID), Stefania Zambelli (ID)
 Answer in writing 
 Subject: Dissemination and support of serology treatment (CCP) for COVID-19 in the European Union

COVID-19 convalescent plasma transfusion (CCP) appears to be one of the most effective and safe forms of treatment, as confirmed by various healthcare institutions.

Ongoing clinical trials at the San Matteo di Pavia general hospital, the Carlo Poma di Mantova hospital and a number of European institutes seem very promising, and the scientific findings will be available shortly.

The Commission, the European Centre for Disease Prevention and Control (ECDC) and the Member States have approved a guidance and monitoring procedure and gathered data on the use of CCP. The Commission has, in the meantime, launched a fundraising effort, for which it has itself pledged EUR 1.4 billion, for the distribution and dissemination of a vaccine for COVID-19, a vaccine that most probably will not be available for at least six months. In light of this, could the Commission answer the following:

1. Should specific funds be allocated to supporting and disseminating CCP and its most recent developments, including through the Commission fundraiser?

2. In light of new developments, will it bring the guidelines up to date and issue a recommendation on the use of treatment with CCP?

3. Does it believe the collection of funds and sharing of data on trials and ongoing use in Member States should be expanded?


(1)This question is supported by Members other than the authors: Marco Zanni (ID), Antonio Maria Rinaldi (ID), Matteo Adinolfi (ID), Silvia Sardone (ID), Vincenzo Sofo (ID), Annalisa Tardino (ID), Paolo Borchia (ID), Isabella Tovaglieri (ID), Francesca Donato (ID), Jean-Paul Garraud (ID)
Original language of question: IT
Last updated: 14 May 2020Legal notice - Privacy policy